Evidence map›Paper›PMID 41009448›Full record

ArticleInternational journal of molecular sciences2025

Determination of a New Biomarker at the Level of Gene Alteration in Cisplatin Ototoxicity.

Deniz Kızmazoğlu, Aylin Erol, Tekincan Çağrı Aktaş, Yüksel Olgun, Ayşe Banu Demir, Zekiye Altun, Safiye Aktaş, Nur Olgun

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Deniz KızmazoğluDepartment of Pediatric Oncology, Institute of Oncology, Dokuz Eylül University, Izmir 35340, Turkey.ORCID 0000-0003-3349-7140
Aylin ErolDepartment of Basic Oncology, Institute of Oncology, Dokuz Eylül University, Izmir 35340, Turkey.
Tekincan Çağrı AktaşDepartment of Basic Oncology, Institute of Oncology, Dokuz Eylül University, Izmir 35340, Turkey.
Yüksel OlgunDepartment of Otorhinolaryngology, Faculty of Medicine, Dokuz Eylül University, Izmir 35340, Turkey.
Ayşe Banu DemirDepartment of Medical Biology, Faculty of Medicine, Izmir University of Economics, Izmir 35330, Turkey.ORCID 0000-0003-4616-8151
Zekiye AltunDepartment of Basic Oncology, Institute of Oncology, Dokuz Eylül University, Izmir 35340, Turkey.
Safiye AktaşDepartment of Basic Oncology, Institute of Oncology, Dokuz Eylül University, Izmir 35340, Turkey.ORCID 0000-0002-7658-5565
Nur OlgunDepartment of Pediatric Oncology, Institute of Oncology, Dokuz Eylül University, Izmir 35340, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cisplatin is an alkylating chemotherapeutic drug used in the treatment of many pediatric solid tumors, and cisplatin ototoxicity is characterized by sensorineural, bilateral, irreversible, and progressive hearing loss. The aim of this study is to identify biomarkers that may serve as predictors of cisplatin-induced ototoxicity in pediatric cancers. In our preliminary study, patients with severe hearing loss were analyzed using the comparative genomic hybridization (CGH) method. Mutations were identified in the following genes:

Indexed as

Antineoplastic AgentsCisplatinHearing LossOtotoxicityAdolescentBiomarkersChildChild, PreschoolComparative Genomic HybridizationFemaleHumansInfantMaleMutationNeoplasmsAntineoplastic AgentsBiomarkersCisplatinbiomarkerscisplatin ototoxicityhearing losspediatric cancer

Identifiers

PMID41009448
PMCPMC12470032

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.